{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T10:08:36Z","timestamp":1772446116024,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-cardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jjcc.2025.11.006","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T17:34:06Z","timestamp":1763660046000},"page":"212-220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Specificities of amyloid cardiomyopathy caused by transthyretin V30 mutation"],"prefix":"10.1016","volume":"87","author":[{"given":"Mariana","family":"Pereira Santos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Pinto Pires","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Fontes Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Monteiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiago","family":"Peixoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"S\u00e1 Couto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Meireles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hip\u00f3lito","family":"Reis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"Luz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patr\u00edcia","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jjcc.2025.11.006_bb0005","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/HCO.0000000000000547","article-title":"Amyloidosis cardiomyopathy: update in the diagnosis and treatment of the most common types","volume":"33","author":"Nativi-Nicolau","year":"2018","journal-title":"Curr Opin Cardiol"},{"issue":"7","key":"10.1016\/j.jjcc.2025.11.006_bb0010","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","article-title":"Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease","volume":"15","author":"Adams","year":"2019","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"10.1016\/j.jjcc.2025.11.006_bb0015","doi-asserted-by":"crossref","first-page":"59","DOI":"10.5334\/gh.1262","article-title":"World Heart Federation consensus on transthyretin amyloidosis cardiomyopathy (ATTR-CM)","volume":"18","author":"Brito","year":"2023","journal-title":"Glob Heart"},{"issue":"36","key":"10.1016\/j.jjcc.2025.11.006_bb0020","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"3\u20134","key":"10.1016\/j.jjcc.2025.11.006_bb0025","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000490553","article-title":"Epidemiology of transthyretin familial amyloid polyneuropathy in portugal: a nationwide study","volume":"51","author":"In\u00eas","year":"2018","journal-title":"Neuroepidemiology"},{"issue":"7","key":"10.1016\/j.jjcc.2025.11.006_bb0030","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1001\/archneur.62.7.1057","article-title":"Transthyretin-related familial amyloidotic polyneuropathy","volume":"62","author":"Ando","year":"2005","journal-title":"Arch Neurol"},{"issue":"2","key":"10.1016\/j.jjcc.2025.11.006_bb0035","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s40120-021-00258-z","article-title":"Characteristics of patients with late- vs. early-onset Val30Met transthyretin amyloidosis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)","volume":"10","author":"Waddington-Cruz","year":"2021","journal-title":"Neurol Ther"},{"issue":"4","key":"10.1016\/j.jjcc.2025.11.006_bb0040","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1136\/jmg.2003.014803","article-title":"Common origin of the Val30Met mutation responsible for the amyloidogenic transthyretin type of familial amyloidotic polyneuropathy","volume":"41","author":"Ohmori","year":"2004","journal-title":"J Med Genet"},{"issue":"8","key":"10.1016\/j.jjcc.2025.11.006_bb0045","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.116.005066","article-title":"Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement","volume":"9","author":"Treibel","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"issue":"3","key":"10.1016\/j.jjcc.2025.11.006_bb0050","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3109\/13506129.2015.1028616","article-title":"Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role","volume":"22","author":"Longhi","year":"2015","journal-title":"Amyloid"},{"issue":"38","key":"10.1016\/j.jjcc.2025.11.006_bb0055","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Casta\u00f1o","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jjcc.2025.11.006_bb0060","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.amjcard.2020.05.021","article-title":"Prevalence, incidence, and impact on mortality of conduction system disease in transthyretin cardiac amyloidosis","volume":"128","author":"Donnellan","year":"2020","journal-title":"Am J Cardiol"},{"issue":"13","key":"10.1016\/j.jjcc.2025.11.006_bb0065","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jacc.2022.01.036","article-title":"Critical comparison of documents from scientific societies on cardiac amyloidosis: JACC state-of-the-art review","volume":"79","author":"Rapezzi","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jjcc.2025.11.006_bb0070","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1093\/ehjci\/jeab154","article-title":"Multimodality imaging in patients with heart failure and preserved ejection fraction: an expert consensus document of the European Association of Cardiovascular Imaging","volume":"23","author":"Smiseth","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"5","key":"10.1016\/j.jjcc.2025.11.006_bb0075","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.jcmg.2020.09.023","article-title":"Radionuclide imaging in the diagnosis of transthyretin cardiac amyloidosis","volume":"14","author":"Rodrigues","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"issue":"16","key":"10.1016\/j.jjcc.2025.11.006_bb0080","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.jjcc.2025.11.006_bb0085","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/13506129.2020.1744553","article-title":"The sensitivity of DPD scintigraphy to detect transthyretin cardiac amyloidosis in V30M mutation depends on the phenotypic expression of the disease","volume":"27","author":"Azevedo Coutinho","year":"2020","journal-title":"Amyloid"},{"issue":"6","key":"10.1016\/j.jjcc.2025.11.006_bb0090","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ejhf.2198","article-title":"Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"21","key":"10.1016\/j.jjcc.2025.11.006_bb0095","doi-asserted-by":"crossref","first-page":"e1999","DOI":"10.1212\/WNL.0000000000006543","article-title":"Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy","volume":"91","author":"Coelho","year":"2018","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.jjcc.2025.11.006_bb0100","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jjcc.2025.11.006_bb0105","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/lt.22184","article-title":"Continuous development of arrhythmia is observed in Swedish transplant patients with familial amyloidotic polyneuropathy (amyloidogenic transthyretin Val30Met variant)","volume":"17","author":"Okamoto","year":"2011","journal-title":"Liver Transpl"},{"issue":"11","key":"10.1016\/j.jjcc.2025.11.006_bb0110","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jjcc.2025.11.006_bb0115","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"issue":"35","key":"10.1016\/j.jjcc.2025.11.006_bb0120","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1093\/eurheartj\/ehab364","article-title":"2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy","volume":"42","author":"Glikson","year":"2021","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.jjcc.2025.11.006_bb0125","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s10741-023-10339-w","article-title":"Sex differences in transthyretin cardiac amyloidosis","volume":"29","author":"Aimo","year":"2024","journal-title":"Heart Fail Rev"},{"issue":"7","key":"10.1016\/j.jjcc.2025.11.006_bb0130","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.hrthm.2012.02.033","article-title":"Prophylactic pacemaker implantation in familial amyloid polyneuropathy","volume":"9","author":"Algalarrondo","year":"2012","journal-title":"Heart Rhythm"},{"issue":"5","key":"10.1016\/j.jjcc.2025.11.006_bb0135","doi-asserted-by":"crossref","DOI":"10.1093\/europace\/euad105","article-title":"Clinical, electrocardiographic, and echocardiographic parameters associated with the development of pacing and implantable cardioverter-defibrillator indication in patients with transthyretin amyloid cardiomyopathy","volume":"25","author":"Kawahara","year":"2023","journal-title":"Europace"},{"issue":"2","key":"10.1016\/j.jjcc.2025.11.006_bb0140","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s10840-019-00517-y","article-title":"Pacemaker implantation in familial amyloid polyneuropathy: when and for whom?","volume":"55","author":"Milner","year":"2019","journal-title":"J Interv Card Electrophysiol"},{"issue":"9","key":"10.1016\/j.jjcc.2025.11.006_bb0145","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.jacep.2020.04.020","article-title":"Cardiac implantable electronic devices: a window into the evolution of conduction disease in cardiac amyloidosis","volume":"6","author":"Rehorn","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"issue":"3","key":"10.1016\/j.jjcc.2025.11.006_bb0150","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jjcc.2024.03.008","article-title":"Atrial fibrillation in the setting of cardiac amyloidosis - a review of the literature","volume":"84","author":"Bazoukis","year":"2024","journal-title":"J Cardiol"},{"issue":"2","key":"10.1016\/j.jjcc.2025.11.006_bb0155","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/jnnp-2014-308107","article-title":"CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings","volume":"86","author":"Maia","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"36","key":"10.1016\/j.jjcc.2025.11.006_bb0160","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.jjcc.2025.11.006_bb0165","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/joim.12585","article-title":"One mutation, two distinct disease variants: unravelling the impact of transthyretin amyloid fibril composition","volume":"281","author":"Suhr","year":"2017","journal-title":"J Intern Med"}],"container-title":["Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508725002825?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0914508725002825?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T09:29:48Z","timestamp":1772443788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0914508725002825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0914508725002825"],"URL":"https:\/\/doi.org\/10.1016\/j.jjcc.2025.11.006","relation":{},"ISSN":["0914-5087"],"issn-type":[{"value":"0914-5087","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Specificities of amyloid cardiomyopathy caused by transthyretin V30 mutation","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2025.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Japanese College of Cardiology. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}